A Phase I/IIa Dose Escalation Study of Repeated Administration of CYT107 (glyco-r-hIL-7) Add On Treatment in Genotype 1 or 4 HCV Infected Patients Resistant To Pegylated Interferon-Alpha and Ribavirin.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 17 Oct 2012
At a glance
- Drugs Interleukin-7; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms ECLIPSE-2
- Sponsors Revimmune SAS
- 17 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 17 Oct 2012 Planned end date changed from 1 Jun 2011 to 1 Mar 2013 as reported by ClinicalTrials.gov record.
- 24 Mar 2012 Planned number of patients changed from 18 to 36 as reported by European Clinical Trials Database.